arrow
G

Giles Robinson

St Jude Children's Research Hospital
H指数:70
被引数:2.4万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency

Divergent medulloblastoma chromatin states disclose KDM2B as a selective dependency 不同小脑髓母细胞瘤染色质状态揭示KDM2B为一种选择性依赖

2026-09-240
OA
Silent Verb Generation During fMRI Reveals Post-Radiotherapy Alterations in Cerebellar–Cerebral Language Regions in Patients Treated for Medulloblastoma

静息状态下动词生成任务下的fMRI揭示接受放射治疗的髓母细胞瘤患者小脑-大脑语言区域的改变

Cancers
IF4.4
2026-08-280
OA
Patient-derived pediatric brain tumor orthotopic xenografts and tumor organoids faithfully recapitulate primary tumors

患者来源的儿童脑肿瘤正位异种移植模型和肿瘤类器官忠实地再现原发肿瘤

2026-04-150
OAAI
M-PACT leverages cell-free DNA methylomes to achieve robust classification of pediatric brain tumors
2026-02-014
PRE
A systematic study of molecular diagnosis, treatment, and prognosis in infant-type hemispheric glioma: An individual patient data meta-analysis of 164 patients

婴儿型半球胶质瘤的分子诊断、治疗及预后系统性研究:一项包含164例患者的个体患者数据荟萃分析

2025-11-080
OA
Efficacy and tolerability of mirdametinib (PD-0325901) in children, adolescents, and young adults with recurrent/progressive low-grade glioma: update from the SJ901 (NCT04923126) phase 1/2 clinical trial

米拉达米替布(PD-0325901)在儿童、青少年和年轻成人复发/进展性低级别胶质瘤中的有效性和耐受性:来自SJ901(NCT04923126)I/II期临床试验的更新

2025-11-010
OAAI
DIVERGENT MEDULLOBLASTOMA CHROMATIN STATES DISCLOSE KDM2B AS A SELECTIVE DEPENDENCY

分化型髓母细胞瘤染色质状态揭示KDM2B为选择性依赖

2025-11-010
OAAI
PHASE 2 STUDY OF ALISERTIB IN COMBINATION THERAPY FOR NEWLY DIAGNOSED ATYPICAL TERATOID/RHABDOID TUMOR (AT/RT)- RESULTS FROM SJATRT STRATA B AND C

II期研究:阿利sertib联合疗法治疗新诊断的畸胎样/横纹肌样瘤(AT/RT)-SJATRT研究B组和C组结果

2025-11-010
OAAI
Enhancing Medulloblastoma Classification: Integrating IHC and DNA Methylation Data from the SJMB12 Clinical Trial

增强髓母细胞瘤分类:整合SJMB12临床试验的IHC和DNA甲基化数据

2025-11-010
OAAI
An integrated analysis of three medulloblastoma clinical trials refines risk-stratification approaches for reducing toxicity and improving survival

对三项髓母细胞瘤临床试验的综合分析,优化了降低毒性和改善生存的风险分层方法

2025-11-010
OA
Molecular insights into response and resistance in children with relapsed/refractory brain tumors on ribociclib combination therapy: results from SJDAWN

关于接受ribociclib联合疗法治疗的复发/难治性脑瘤患儿的应答与耐药性的分子机制研究:SJDAWN研究的结果

2025-11-010
OAAI
AN ONCOGENIC PHOTORECEPTOR PROGRAM UNIFIES DISTINCT CENTRAL NERVOUS SYSTEM TUMORS

一个致癌的光感受器程序统一了不同类型的中央神经系统肿瘤

2025-11-010
OAAI
Robust classification of pediatric brain tumors from cell-free DNA methylomes

基于游离细胞DNA甲基组的儿童脑肿瘤鲁棒性分类

2025-11-010
OAAI
Locoregional B7-H3 CAR-T cells for relapsed/refractory CNS tumors: preliminary clinical experience of the Loc3CAR trial

局部区域B7-H3 CAR-T细胞治疗复发/难治性中枢神经系统肿瘤:Loc3CAR试验的初步临床经验

2025-11-010
OAAI
Tumor inflammation-associated neurotoxicities for patients treated with intracranial B7-H3-CAR T cells on a phase I clinical trial

I期临床试验中接受颅内B7-H3-CAR T细胞治疗的患者的肿瘤炎症相关神经毒性

2025-11-010
OAAI
Genetic modeling of ELP1-associated Sonic hedgehog medulloblastoma identifies MDM2 as a selective therapeutic target

ELP1相关Sonic hedgehog型髓母细胞瘤的遗传建模识别MDM2为选择性治疗靶点

2025-11-010
PRE
Nuclear Transport as a Therapeutic Vulnerability in ZFTA-RELA Ependymoma

ZFTA-RELA室管膜瘤中核转运作为治疗性易损靶点

2025-11-010
OAAI
Molecular characterization of the SJMB12 clinical trial for children and young adults with newly diagnosed medulloblastoma

SJMB12临床试验的分子特征分析:针对新诊断髓母细胞瘤的儿童及青少年患者

2025-11-010
PRE
INTEGRATED MULTI-OMIC PROFILING REVEALS PROTEOMIC HETEROGENEITY AND PATHWAY DYNAMICS IN MEDULLOBLASTOMA

整合多组学分析揭示了髓母细胞瘤中的蛋白质组异质性和通路动态。

2025-11-010
OAAI